Seres Therapeutics Stock Today
| MCRB Stock | USD 0.73 0.03 3.95% |
Performance0 of 100
| Odds Of DistressOver 73
|
Seres Therapeutics is trading at 0.73 as of the 24th of April 2024, a -3.95 percent down since the beginning of the trading day. The stock's open price was 0.76. Seres Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Seres Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 25th of January 2024 and ending today, the 24th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 26th of June 2015 | Category Healthcare | Classification Health Care |
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. The company has 151.01 M outstanding shares of which 18.8 M shares are now shorted by private and institutional investors with about 4.14 trading days to cover. More on Seres Therapeutics
Moving against Seres Stock
| 0.76 | XFOR | X4 Pharmaceuticals Financial Report 2nd of May 2024 | PairCorr |
| 0.7 | NRSNW | NeuroSense Therapeutics | PairCorr |
| 0.69 | ELEV | Elevation Oncology Financial Report 20th of May 2024 | PairCorr |
| 0.65 | CGC | Canopy Growth Corp Trending | PairCorr |
| 0.64 | ACB | Aurora Cannabis Trending | PairCorr |
| 0.59 | VKTX | Viking Therapeutics Earnings Call Today | PairCorr |
| 0.55 | ELYM | Eliem Therapeutics | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 14th of May 2024
Seres Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Seres Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Seres Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO President | Eric MBA | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation Analysts covering Seres Therapeutics report their recommendations after researching Seres Therapeutics' financial statements, talking to executives and customers, or listening in on Seres Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Seres Therapeutics. The Seres consensus assessment is calculated by taking the average forecast from all of the analysts covering Seres Therapeutics. | |||||
Seres Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Seres Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Seres Therapeutics' financial leverage. It provides some insight into what part of Seres Therapeutics' total assets is financed by creditors.
| |||||
Seres Therapeutics (MCRB) is traded on NASDAQ Exchange in USA. It is located in 101 Cambridgepark Drive, Cambridge, MA, United States, 02140 and employs 233 people. Seres Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 112.05 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Seres Therapeutics's market, we take the total number of its shares issued and multiply it by Seres Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Seres Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 151.01 M outstanding shares of which 18.8 M shares are now shorted by private and institutional investors with about 4.14 trading days to cover.
Seres Therapeutics currently holds about 195.8 M in cash with (117.35 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.58, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Seres Therapeutics Probability Of Bankruptcy
Ownership AllocationSeres Therapeutics shows a total of 151.01 Million outstanding shares. Over half of Seres Therapeutics' outstanding shares are owned by institutional holders. These institutional holders are typically referred to as corporate investors that take positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulations than regular investors in Seres Therapeutics. Please watch out for any change in the institutional holdings of Seres Therapeutics as this could mean something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Seres Ownership Details
Seres Stock Price Odds Analysis
What are Seres Therapeutics' target price odds to finish over the current price? Depending on a normal probability distribution, the odds of Seres Therapeutics jumping above the current price in 90 days from now is about 84.13%. The Seres Therapeutics probability density function shows the probability of Seres Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 3.3751. This indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Seres Therapeutics will likely underperform. Additionally, seres Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of Seres Therapeutics to move above the current price in 90 days from now is about 84.13 (This Seres Therapeutics probability density function shows the probability of Seres Stock to fall within a particular range of prices over 90 days) .
Seres Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Seres Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Seres Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Seres Therapeutics' value.| Instituion | Recorded On | Shares | |
| Susquehanna International Group, Llp | 2023-12-31 | 1.4 M | |
| Woodline Partners Lp | 2023-12-31 | 1.3 M | |
| Handelsbanken Fonder Ab | 2023-12-31 | 1.1 M | |
| Morgan Stanley - Brokerage Accounts | 2023-12-31 | 885.3 K | |
| Goldman Sachs Group Inc | 2023-12-31 | 871.7 K | |
| Renaissance Technologies Corp | 2023-12-31 | 817 K | |
| Northern Trust Corp | 2023-12-31 | 770.6 K | |
| Charles Schwab Investment Management Inc | 2023-12-31 | 676.4 K | |
| Qube Research & Technologies | 2023-12-31 | 640.7 K | |
| Flagship Ventures Management, Inc. | 2023-09-30 | 23.1 M | |
| Fmr Inc | 2023-12-31 | 19.4 M |
Seres Therapeutics Historical Income Statement
Seres Therapeutics Income Statement is one of the three primary financial statements used for reporting Seres's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Seres Therapeutics revenue and expense. Seres Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At present, Seres Therapeutics' Depreciation And Amortization is projected to increase significantly based on the last few years of reporting. The current year's Interest Expense is expected to grow to about 13.8 M, whereas Other Operating Expenses is forecasted to decline to about 125.5 M. View More FundamentalsSeres Stock Against Markets
Picking the right benchmark for Seres Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Seres Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Seres Therapeutics is critical whether you are bullish or bearish towards Seres Therapeutics at a given time. Please also check how Seres Therapeutics' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Seres Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Headlines Timeline Now
Headlines TimelineStay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |
| All Next | Launch Module |
Seres Therapeutics Corporate Directors
Seres Therapeutics corporate directors refer to members of a Seres Therapeutics board of directors. The board of directors generally takes responsibility for the Seres Therapeutics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Seres Therapeutics' board members must vote for the resolution. The Seres Therapeutics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Lorence Kim | Independent Director | Profile | |
| Dennis Ausiello | Director | Profile | |
| Willard Dere | Director | Profile | |
| Peter Hutt | Director | Profile |
How to buy Seres Stock?
Before investing in Seres Therapeutics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Seres Therapeutics. To buy Seres Therapeutics stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Seres Therapeutics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Seres Therapeutics stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Seres Therapeutics stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Seres Therapeutics stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Seres Therapeutics, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Seres Stock please use our How to Invest in Seres Therapeutics guide.
Already Invested in Seres Therapeutics?
The danger of trading Seres Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Seres Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Seres Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Seres Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Seres Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Seres Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Seres Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Seres Therapeutics Stock: Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Seres Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Seres Stock refer to our How to Trade Seres Stock guide.You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Complementary Tools for Seres Stock analysis
When running Seres Therapeutics' price analysis, check to measure Seres Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Seres Therapeutics is operating at the current time. Most of Seres Therapeutics' value examination focuses on studying past and present price action to predict the probability of Seres Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Seres Therapeutics' price. Additionally, you may evaluate how the addition of Seres Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |
Is Seres Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Seres Therapeutics. If investors know Seres will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Seres Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.89) | Revenue Per Share 0.987 | Quarterly Revenue Growth (0.93) | Return On Assets (0.19) | Return On Equity (5.39) |
The market value of Seres Therapeutics is measured differently than its book value, which is the value of Seres that is recorded on the company's balance sheet. Investors also form their own opinion of Seres Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Seres Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Seres Therapeutics' market value can be influenced by many factors that don't directly affect Seres Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Seres Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Seres Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Seres Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.